Swainsonine

Drug Profile

Swainsonine

Latest Information Update: 18 Jul 2002

Price : $50

At a glance

  • Originator Fujisawa; National Cancer Institute (Canada); Nonindustrial source
  • Developer Fujisawa; National Cancer Institute (Canada)
  • Class Alkaloids
  • Mechanism of Action Immunostimulants; Lymphocyte stimulants; Macrophage stimulants; Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 18 Jan 2001 Profile reviewed but no significant changes made
  • 27 Aug 1997 A study has been added to the therapeutic trials, pharmacodynamics, pharmacokinetics and adverse events sections
  • 27 Aug 1997 Phase-I clinical trials for Cancer in Canada (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top